Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Label indication YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD) . FDA label
Also known as Revefenacin Inhalation Solution [Yupelri]
Revefenacin · 1 trial · 2 indications
Reduction in total inspiratory resistance across the airways and ventilator circuit measured by the change in Static Resistance (Rstat) at the time of drug trough
| Arm | Type | Description |
|---|---|---|
| Revefenacin | EXPERIMENTAL | Revefenacin will be delivered once daily via nebulizer. In order to allow for full blinding and steady Q6 hours regimen in control arm, at hours 6, 12 and 18 after the Revefenacin dose, nebulized normal saline will be delivered. |
| Ipratropium | ACTIVE_COMPARATOR | Nebulized ipratropium will be delivered via nebulizer Q6 hours. |
| Name | Type | Description |
|---|---|---|
| Revefenacin Inhalation Solution [Yupelri] | DRUG | nebulized drug comparison |
| Ipratropium Bromide | DRUG | nebulized drug comparison |
Inclusion Criteria: * Adults ≥ 40 years of age * Acute respiratory failure requiring invasive mechanical ventilation * Documented history of COPD based on spirometric evidence of FEV1/FVC\<70% * Smoking history \>10 years (current or prior) * Invasive mechanical ventilation for \< 96 hours Exclusi...
Top 9 of 12 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 5 | PHASE3 | Depemokimab, GSK3862995B |
| AstraZeneca PLC | AZN | 14 | PHASE3 | Tezepelumab, Breztri, Bevespi, AZD6793, Budesonide/formoterol |
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Lunsekimig, SAR447537, Dupilumab |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Alpha-1 MP |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07275315 |
| Merck & Co., Inc. | MRK | 2 | PHASE2 | Frespaciguat, Ensifentrine |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Generate Biomedicines, Inc. | GENB | 1 | PHASE1 | GB-0895 |
| United Therapeutics Corporation | UTHR | 1 | PHASE2 | Tyvaso (treprostinil) |
Revefenacin is an investigational small molecule developed for chronic obstructive pulmonary disease (COPD), a respiratory condition. It has also been studied in acute respiratory insufficiency in COPD. The drug is being developed by Theravance Biopharma, Inc. (TBPH) and remains in clinical development.
Revefenacin targets CHRM3, the M3 muscarinic acetylcholine receptor, and acts as an antagonist. By blocking this receptor, it is designed to reduce bronchoconstriction in the airways. This mechanism is relevant to its development for COPD and acute respiratory insufficiency.
Revefenacin is developed by Theravance Biopharma, Inc., which trades under the ticker TBPH. The company is responsible for its clinical development in respiratory indications, including COPD.
Revefenacin is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA for any indication. The Phase 2 trial for acute respiratory insufficiency in COPD has been completed.
Revefenacin has been studied in one completed Phase 2 trial, NCT04315558, titled "Revefenacin in Acute Respiratory Insufficiency in COPD." The trial enrolled 21 participants in the United States, was randomized, double-blind, and active-controlled, and included biomarker-selected patients.
Revefenacin is also known as Revefenacin Inhalation Solution [Yupelri]. These names refer to the same active ingredient, revefenacin, which is being developed by Theravance Biopharma for respiratory conditions including COPD.